Salamanca

• A clinical trial to learn about the effects of YTB323 in people with difficult to treat severe diffuse cutaneous systemic sclerosis (dcSSc) Recruiting
  2023-510380-34-00 4 2024-12-10 Diffuse cutaneous systemic sclerosis (dcSSc)
• A Phase 1 Study of BMS-986453 in Participants with Relapsed and/or Refractory Multiple Myeloma Recruiting
  2023-506003-26-00 1 2024-11-27 Relapsed and/or Refractory Multiple Myeloma
• Use of statins in patients with intracerebral hemorrhage Recruiting
  2024-511465-11-00 5 2024-11-20 Spontaneous lobar ICH
• LATE-R trial. A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients with Lat … Recruiting
  2024-512835-53-00 4 2024-11-20 Diffuse Large B-Cell Lymphoma
• Bomedemstat vs Hydroxyurea for Essential Thrombocythemia Recruiting
  2023-505232-36-00 5 2024-11-15 Essential thrombocythemia
• Study of MEN1703 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Recruiting
  2024-513098-31-00 4 2024-11-14 Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
• Letermovir (LMV) prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients with CMV seropositive donors Recruiting
  2024-516011-24-01 4 2024-11-13 Cytomegalovirus infection in allogeneic stem cell transplant recipient
• Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting
  2023-504724-25-00 5 2024-10-16 Primary Myelofibrosis
• A Study to Evaluate ARV-393 in Adult Participants with Advanced Non-Hodgkin’s Lymphoma Recruiting
  2023-510136-36-00 1 2024-09-27 Advanced Non-Hodgkin’s Lymphoma
• A Phase 2/3 study to evaluate safety and efficacy of the combination of Bel- CHOP/ Fol-COP drugs against CHOP in newly diagnosed Peripheral … Recruiting
  2023-507803-76-00 10 2024-09-26 Peripheral T-Cell Lymphoma
• A Window of Opportunity Trial To Learn If Linvoseltamab Is Safe And Well Tolerated, And How Well It Works In adult Participants With Recentl … Recruiting
  2022-500800-24-00 4 2024-09-19 Multiple Myeloma
• A multicenter, phase 2 randomized, open label study to evaluate the efficacy and security of zanubrutinib in combination with obinutuzumab i … Recruiting
  2023-504647-14-00 4 2024-09-02 Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
• A Study of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas Recruiting
  2023-503550-13-00 7 2024-08-08 Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
• A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on … Recruiting
  2022-502135-19-00 4 2024-07-18 Calcific Aortic Valve Stenosis
• A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate … Recruiting
  2024-511309-47-00 4 2024-07-17 moderate thrombocytopenia
• Prospective, multicenter, open-label study to evaluate the efficacy of esmolol in the early identification of cardiovascular disorders induc … Recruiting
  2024-514880-25-00 5 2024-06-27 Patients with cardiovascular alterations induced by cirrhosis, diabete
• A trial to learn if AZD0305 alone and in combination with other cancer treatments is safe and works in adults with multiple myeloma Recruiting
  2023-508590-89-00 7 2024-06-25 Multiple Myeloma
• A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants … Recruiting
  2022-501697-19-01 5 2024-06-18 Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma
• A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un … Recruiting
  2023-508613-17-00 5 2024-05-29 Neoplasms, Head and Neck
• C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL … Recruiting
  2023-507871-23-00 5 2024-05-27 Relapsed/Refractory Multiple Myeloma
• Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate c … Recruiting
  2023-505024-62-01 4 2024-05-16 Oligometastatic patients with castration-resistant prostate cancer
• CHOP PLUS MOSUNETUZUMAB AS FIRST LINE IN PATIENTS WITH RICHTER´S SYNDROME: A PHASE II STUDY OF THE SPANISH GROUP OF CLL (GELLC-9-RICHTER) Recruiting
  2023-505621-13-00 4 2024-05-14 Richter´syndrome
• Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy Recruiting
  2024-513601-31-00 4 2024-05-13 Acute lymphoid leukemia

Showing 145–168 of 470 trials